Business
Personalis Reports Second Quarter 2025 Financial Results
FREMONT, Calif., August 05, 2025--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy:
About this update from Tempus Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2d30a31070021c1625fd88155afc8942"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vEtDNVXGQ_h9JFa.JsHbjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2d30a31070021c1625fd88155afc8942","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xUsqN4cp.QI0dnROQFPjcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/2d30a31070021c1625fd88155afc8942","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume","length":69,"tagName":"p","attribs":{}},{"type":"text","content":"FREMONT, Calif., August 05, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy:","length":281,"tagName":"p"},{"type":"text","content":"Second Quarter 2025 and Recent Business Highlights","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform","length":202,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc. (Tempus) to add colorectal cancer, a major new indication, to the exclusive commercialization agreement, positioning Personalis to win in this attractive market","length":253,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"World-Class Clinical Evidence Generation: Presented pivotal data at the 2025 ASCO Annual Meeting, including results from the PREDICT and SCANDARE studies showing NeXT Personal’s ability to predict therapy response in breast cancer. Notably, nearly half of all positive detections were found in the ultra-sensitive range","length":319,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Clin...